Last reviewed · How we verify
NCT07287176: PRECISE-BTN
Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System
NA trial testing nPulse Vybrance Percutaneous Electrode System in Thyroid Nodule in 100 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Pulse Biosciences, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 21 August 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- nPulse Vybrance Percutaneous Electrode System
Conditions studied
- Thyroid Nodule — all drugs for Thyroid Nodule →
- Thyroid Goiter — all drugs for Thyroid Goiter →
- Ablation — all drugs for Ablation →
Sponsor
Pulse Biosciences, Inc.
Who can join
Adults 22 to 80, any sex, with Thyroid Nodule or Thyroid Goiter. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07287176
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Nodule
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07488325 — Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytol · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT06730321 — Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment · recruiting
- NCT06733753 — Ultrasound-guided Thermal Ablation for Bethesda III/IV Thyroid Nodules · recruiting
Other Pulse Biosciences, Inc. trials
Trials by the same sponsor.
- NCT06355063 — CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation · NA · recruiting
- NCT06696170 — CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation · NA · recruiting
- NCT06117085 — CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules · NA · completed
- NCT04918381 — CellFX Treat & Resect Low-Risk BCC Feasibility Study · NA · completed
- NCT04738734 — CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07287176 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pulse Biosciences, Inc.
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07287176.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing